medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2017, Number 4

<< Back Next >>

Acta Med 2017; 15 (4)

Triple-negative breast cancer: frequency and characteristics at Hospital Ángeles Pedregal

Hernández-Álvarez C, Romo-Aguirre C, Ortiz-de Iturbide C

Language: Spanish
References: 21
Page: 269-274
PDF size: 256.75 Kb.


ABSTRACT

Background: Breast cancer is the leading cause of death in women in Mexico; it is a heterogeneous disease that requires a multidisciplinary approach. Objective: To review the anatomopathological and immunohistochemical characteristics in triple-negative breast cancer patients described in the Mexican population and compare them with the sample reported from January 2009 to August 2015 at the Hospital Ángeles Pedregal. Material and methods: We conducted a cross-sectional, descriptive and retrospective study of patients with diagnosis of triple-negative breast cancer and mammography studies performed during the period from January 2009 through August 2015 at the Hospital Ángeles Pedregal. Results: We identified 3,290 breast tissue specimens, 600 (18.24%) with histopathologic diagnosis of breast cancer. Triple-negative breast cancer was reported in 58 cases (9.6%). Average age of diagnosis: 56 years; histological type: 80.13% infiltrating ductal carcinoma; average tumor size ‹ 20 mm: 55.31%. Mammography, 32 cases: BIRADS 5 (6.25%), BIRADS 4 (75%), BIRADS 3 (18.75%). Conclusions: This study showed an average age of diagnosis of 56 years, suitable mammographic and histopathologic correlation, tumor size ‹ 2 cm in half the cases, with characteristics similar to other studies reported in Mexican population.


REFERENCES

  1. De la Vara-Salazar E, Suárez-López L, Ángeles-Llerenas A, Torres-Mejía G, Lazcano-Ponce E. Tendencias de la mortalidad por cáncer de mama en México, 1980-2009. Salud pública Méx. 2011; 53 (5): 385-393.

  2. Hartmann WH. Minimal breast cancer. An update. Cancer. 1984; 53 (3 Suppl): 681-684.

  3. Hernández-Paz JR. Cáncer de mama triple negativo. Experiencia en pacientes del INCAN [Tesis]. México: Instituto Nacional de Cancerología; 2013.

  4. Melcior-Sentís C, Tortajada-Giménez L. Características de imagen del carcinoma triple negativo. Rev Senol Patol Mamar. 2012; 25 (1): 22-31.

  5. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer. 1992; 70 (10): 2468-2474.

  6. Olaya-Guzmán EJ. Cáncer de mama triple negativo, estado actual. Rev Esp Med Quir. 2010; 15 (4): 228-236.

  7. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993; 11 (11): 2090-2100.

  8. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer. 1994; 73 (3): 664-667.

  9. Rasmussen BB, Pedersen BV, Thorpe SM, Rose C. Elastosis in relation to prognosis in primary breast carcinoma. Cancer Res. 1985; 45 (3): 1428-1430.

  10. Masters JR, Sangster K, Hawkins RA, Shivas AA. Elastosis and oestrogen receptors in human breast cancer. Br J Cancer. 1976; 33 (3): 342-343.

  11. Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ. Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer. 1986; 58 (5): 1076-1081.

  12. Butler JA, Bretsky S, Menendez-Botet C, Kinne DW. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer. 1985; 55 (6): 1178-1181.

  13. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11 (2): 155-168.

  14. De Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M et al. Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas, concordance with biochemical assay and prognostic significance. Appl Immunohistochem. 1995; 3 (4): 222-231.

  15. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011; 117 (16): 3658-3669.

  16. Gerson R, Alban F, Villalobos A, Serrano A. Recurrencia y supervivencia en cáncer mamario temprano con inmunofenotipo triple negativo. Gac Med Mex. 2008 144 (1): 27-34.

  17. Pérez-Rodríguez G. Prevalencia de subtipos por inmunohistoquímica del cáncer de mama en pacientes del Hospital General Regional 72, Instituto Mexicano del Seguro Social. Cir Cir. 2015; 83 (3): 193-198.

  18. Maffuz-Aziz A, Labastida-Almendaro S, Espejo-Fonseca A, Rodríguez-Cuevas S. Características clinicopatológicas del cáncer de mama en población de mujeres en México. Cir Cir. 2017; 85 (3): 201-207.

  19. Wilbur DC, Willis J, Mooney RA, Fallon MA, Moynes R, di Sant’Agnese PA. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Mod Pathol. 1992; 5 (1): 79-84.

  20. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989; 49 (4): 1052-1056.

  21. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999; 112 (1 Suppl 1): S53-S67.




2020     |     www.medigraphic.com